in inflammation and fibrosis
Laurent Pharma is a late stage clinical biotech company focusing on developing treatments for complex conditions caused by an unbalanced immune-inflammatory response.
Targeting cell membrane lipid composition and fluidity as a new paradigm for regulating host defense and the inflammation process.
Laurent Pharma has completed two Phase 2 clinical studies with LAU-7b, a first-in-class proresolving drug candidate, in cystic fibrosis and COVID-19.
LAU-7b is an oral drug candidate that showed potential to regulate membrane lipids and exert antiviral, inflammation-controlling, and antifibrotic properties.
News & Events
Laurent Pharma to participate to BIO International Convention, June 5-8, 2023, Boston, MA
LAU-7b featured in The Pharmaceutical Journal (The Royal Pharmaceutical Society) among next-generation antivirals targeting COVID-19